Up to £4 million capital investment is available to businesses, universities, hospitals and research and technology organisations to enable research into antimicrobial resistance and advance the development of new products.
The programme has a total budget of £4 million.
Funding awards are likely to be in the range of £200,000 and £2 million. Exceptional applications may be awarded more and organisations can request less than £200,000.
IUK expects to fund between two and 12 projects.
The Government published the UK’s 5 Year Antimicrobial Resistance Strategy in 2013. Covering the period 2013 to 2018, the strategy acknowledged that a substantial and extended research effort is needed to address the emergence and spread of AMR. It also recognised the need for more research to speed up the development of new antimicrobials and new technologies to tackle AMR.
The global threat posed by AMR is also recognised by the independent review led by Lord O’Neill of Gatley. His review estimates that failure to tackle drug-resistant infections will lead to at least 10 million extra deaths a year and cost the global economy up to USD $100 trillion (£75 trillion) by 2050.
Drug resistance forms of a diverse range of common pathogens now exist, but of more concern is the level of multidrug resistance that is emerging. Staphylococcus aureus infections resistant to both meticillin and vancomycin are well documented and extremely drug resistant/totally drug resistant forms of Mycobacterium tuberculosis are of global concern.
Innovate UK is running a competition to build on the UK’s capability in AMR research, with particular reference to innovative drugs, diagnostics and vaccines to tackle drug-resistant bacteria. The ultimate aim is to stimulate partnerships of excellence across the UK with strong public/private collaboration in the UK. This should stimulate translation, shorten concept to commercialisation, and provide a support mechanism to small innovative companies, in line with the recommendations of the O’Neill report.
The aim will be to develop new products and services that will reduce the impact of drug-resistant pathogens, slow down the emergence of new ones, and produce new drugs, vaccines and diagnostics.
Focusing on antibacterial resistance, the competition aims to:
- strengthen research and innovation excellence across the UK;
- maximise private sector engagement and leverage funding;
- capitalise on existing UK expertise in AMR research and innovation;
- support and use capability in different regions.
Projects need to demonstrate that the capital investment grant they’re requesting will:
- advance the UK’s ability to tackle the global challenges of antimicrobial resistance (AMR);
- encourage public/private partnerships and maximise further investment.
Applications that do not address antibacterial resistance will be out of scope.
This competition is not looking for projects involved in new soaps, disinfectants or advanced materials to decrease contamination.
NB: New antibacterial wound dressings and coatings on ventilator tubes etc, will be in scope.
Funding cannot be used towards salaries or consumables.
The competition project is open to any UK organisation working on its own or in a consortium. IUK will encourage with companies, universities and other research establishments.
To apply for funding the applicant must:
- be a UK based organisation;
- be an organisation of any size or type (any organisation can lead a consortium);
- carry out a project in the UK (although applicants can collaborate with international organisations);
- work alone or in a consortium with other UK organisations. A consortium can be made up of any type of UK organisation including businesses, charities, universities and hospitals and any mix of these;
- satisfy the criterion that any equipment purchased or refurbished should be used for AMR-related activities at least 80% of the time.
Companies can only apply for 50% of the total eligible capital costs they are requesting. Universities, hospitals, and research and technology organisations can apply for 100% of their total costs.
This competition is for capital investment, including refurbishment and equipment. Capital can include the cost of setting up equipment but not the costs of maintenance or staff.
Note: Any equipment purchased or refurbishment should be used for AMR related activities at least 80% of the time.
Examples of in-scope applications include but are not limited to bids that aim to:
- create an infrastructure that will fast-track the research, development, evaluation and commercialisation of new drugs, diagnostics and vaccines;
- establish a global multi-centre clinical trials network for drugs, diagnostics and vaccines. This should address major drug-resistant pathogens;
- build on existing UK infrastructure and set up a sample collection network. This should be via an individual AMR portal from local and international networks that will enable quality research;
- establish databases for new scientific and public health understanding of AMR.
All applications must focus on reducing the impact of antibacterial resistance on human health.
- The competition opened on 14 September 2016.
- The deadline for registrations was noon on 27 October 2016.
- The deadline for full applications was noon on 2 November 2016.
- Attend in person or by webinar the briefing event in London on 19 September 2016 (now passed).
Link to guidelines:
For this competition, Innovate UK, with the Department of Health, will adopt a portfolio approach. This is to make sure that the strategic criteria described in the competition brief, are met for all projects considered to be above the quality threshold. This will be as a result of independent expert assessment.
- Applications will be assessed by up to five external assessors who are experts in the area of innovation identified in the application.
- Assessors will score applications consistently and in line with scoring matrices. They will provide written feedback for each marked question.
- Applications will be ranked in descending order. Applications scoring over a quality threshold will be reviewed against the Department of Health’s goals for this competition and applicants may be invited for interview.
- Following interviews the expert panel will review with the Department of Health and Innovate UK all quality applications, including any not invited for interview, and build a portfolio of projects that:
- are high quality
- together have the potential to have the greatest impact on AMR
- will build capability across the UK
- demonstrate sufficient potential return on investment
- demonstrate value for money, include the potential impact relative to its cost, and the cost of other projects under consideration
- The applicant will be notified of the funding decision.
- All applications will receive assessor feedback. In addition, those invited to interview will receive extra feedback from the portfolio review.
|Competition opens||14 September 2016|
|Briefing event/webinar||London, 19 September 2016|
|Registration deadline||Noon 27 October 2016|
|Deadline for applications||Noon 2 November 2016|
by invitation only
|29 November 2016
please keep date free
|Contracts awarded||By December 2016|